# One Inflammatory Switch, Two Peptides > municipalpeptides — Immune & Thymic Research Peptides — municipalpeptides maps the peer-reviewed research on thymulin and KPV, two peptides studied for immune modulation, through the lens of immunomodulation research. Cited summaries, no dosing advice. **IMMUNE & THYMIC RESEARCH** A data-forward reading of the published research on thymulin and KPV — a zinc-locked thymic hormone and a gut-targeted alpha-MSH fragment, both studied for their effect on NF-kB signaling. ### [Thymulin](/thymulin) A zinc-dependent thymic nonapeptide studied for T-cell modulation and anti-inflammatory signaling — in a 2020 gene-therapy model, it reversed already-established lung inflammation in mice. ### [KPV](/kpv) A tripeptide fragment of alpha-MSH studied almost entirely in murine colitis models, where targeted nanoparticle delivery suppresses gut inflammation without the pigment effects of its parent hormone. ## The short version municipalpeptides is a data-forward guide to two peptides studied for immune modulation: **thymulin** and **KPV**. Both come from the body's own signaling systems — thymulin is made by cells in the thymus, the gland that trains immune cells early in life; KPV is a small fragment cut from a hormone called alpha-MSH. In lab and animal studies, both peptides calm an overactive immune response by turning down a signaling switch called NF-kB, which cells use to ramp up inflammation. The two peptides are studied in different settings. Thymulin research spans zinc biology, lung inflammation, and the thymus's link to hormone signaling, with some of the field's oldest work measured directly in people. KPV research is almost entirely about the gut, testing whether nanoparticle-delivered peptide can calm inflammatory bowel disease in mice. This site lays out what each study actually found, cites the source for every number, and never recommends a dose. ## What are research peptides? Peptides are short chains of amino acids — the same building blocks that make up larger proteins, just far fewer of them strung together. Thymulin is a nine-amino-acid peptide (a *nonapeptide*) that only works once it binds a zinc ion; without zinc, the same amino acid chain is inactive. KPV is a three-amino-acid peptide (a *tripeptide*) clipped from the tail end of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone better known for controlling skin pigment — but the KPV fragment keeps the parent hormone's anti-inflammatory signal while dropping the pigment-related one. Neither thymulin nor KPV is an approved drug. Both are sold by chemical suppliers as research peptides — for laboratory use, not human use — and the literature behind them is mostly preclinical: cell cultures and animal models, with thymulin carrying some directly human data from zinc-status studies decades old. ## How thymulin and KPV frame immunomodulation research Thymulin and KPV sit on this desk together because both illustrate the same organizing idea in immunomodulation research: a short peptide, turning down one inflammatory signaling pathway, produces outsized effects at the tissue level. [**Thymulin**](/thymulin) is the lead compound here. Its activity depends entirely on zinc — strip the zinc away and the peptide goes inactive [7] — which makes it as much a marker of zinc-driven immune competence as a therapeutic candidate in its own right. In mice, restoring thymulin signaling by gene therapy reversed an already-established model of allergic asthma [1], and in a separate model it suppressed the same NF-kB pathway that drives much of chronic inflammation [3]. [**KPV**](/kpv), by contrast, is almost entirely a gut-inflammation story. Every recent KPV paper on this desk is a formulation study — testing whether nanoparticles, hydrogels, or targeted carriers can get a fragile three-amino-acid peptide into inflamed colon tissue intact, where it then suppresses the same NF-kB machinery thymulin targets, but locally [8][9][10]. Read together, the two compounds show the immune system's inflammatory brake being tested at two very different points of entry — one systemic and hormone-linked, one local and delivery-engineered. ## How this site reads the evidence Every claim on municipalpeptides carries a citation, and every citation is checked against the study it names — species, model, the dose used in the study (never a recommendation), and outcome. Where a finding comes from a review rather than a primary trial, the text says so. Where the evidence is animal-only, or in vitro-only, or decades old, the text says that too, rather than smoothing it into a confident-sounding sentence. Thymulin and KPV are both preclinical-leaning bodies of literature — modern human trial data exist for neither peptide with any depth beyond thymulin's older zinc-status work — so this site treats every number as belonging to the study it came from: a percentage from a 20-day mouse model is a fact about that model, not a forecast about a person. Compare the two peptides directly on the [comparison page](/compare), or start with either one below. --- A data-forward literature survey of thymic and anti-inflammatory peptide research — every figure traced to its source, nothing sold, no dose advised.